Abstract

Depressive symptoms are the second most common neuropsychiatric symptom (NPS) in dementia, and there are compelling arguments linking depression and amyloid deposition in the brain. Clinical trials on anti-amyloid treatment are primarily focused on cognitive and functional decline: participants with Alzheimer’s disease (AD) and significant psychiatric symptoms are typically excluded from anti-amyloid treatment, and the amelioration of depressive symptomatology is not considered as an outcome. The aim of this opinion article is to analyze whether, given the known association between depression and AD, people with depression should still be excluded from anti-amyloid treatment. Considering the scenario of their inclusion, we shall analyze which factors might interfere with the proper functioning of the anti-amyloid treatment.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.